Latest news with #ShelterMe:TheCancerPioneers
Business Wire
02-05-2025
- Entertainment
- Business Wire
Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies
LOS ANGELES--(BUSINESS WIRE)--The official trailer for ' Shelter Me: The Cancer Pioneers' has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the emotional and inspiring journey of dogs helping to pioneer cancer treatments that are saving human lives. The movie will stream through the PBS app and on starting on Thursday, May 15. The newest film in the Emmy Award-winning 'Shelter Me' series, 'The Cancer Pioneers' brings viewers inside cutting-edge clinical trials where dogs with cancer are being treated with breakthrough immunotherapies, which are leading to treatments that are now extending and saving human lives, thanks to a revolutionary field of science called comparative oncology. The official trailer is available now at 'This is one of the most powerful and consequential stories I've ever told,' said Steven Latham, 'Shelter Me' series Creator and Producer. 'Dogs are helping unlock the future of cancer treatment for people, and the results are incredibly promising.' The documentary features leading scientists and veterinarians from world-renowned institutions including the National Institutes of Health, the National Cancer Institute, the University of Pennsylvania, the University of Illinois, the University of Wisconsin and Colorado State University. These scientists, researchers and veterinarians are working at the forefront of immunotherapy and cancer research, alongside beloved pets who are not only patients, but pioneers in their own right. The official trailer captures the emotional stakes of the film: dogs that are beloved family members fighting cancer, dedicated and brave people, brilliant scientists and a future where hope comes on four legs. ' Shelter Me: The Cancer Pioneers ' is a powerful reminder of the unbreakable bond between humans and animals and how that relationship may hold the key to curing cancer. 'These therapies represent years of dedicated research and collaboration,' said Paul Romness, CEO of OS Therapies. 'Veterinary oncology is now changing the trajectory of treatment for osteosarcoma patients. This film captures the real-world impact of that science.' 'Shelter Me: The Cancer Pioneers' is the latest installment in the acclaimed 'Shelter Me ' series, which has aired nationally on PBS and inspired millions with its uplifting, animal-centered storytelling. The Shelter Me series is presented by Petco Love. Screening opportunities and additional materials are available upon request. To learn more about the 'Shelter Me' series visit About 'Shelter Me: The Cancer Pioneers' 'Shelter Me: The Cancer Pioneers" is about groundbreaking clinical trials for dogs with cancer which is leading to new treatments for people. Featuring leading scientists at the National Cancer Institute, National Institutes of Health and universities across the country. This field of science is called comparative oncology and dogs are leading the way for new immunotherapies. Dogs are amazing and are helping save our lives! 'Shelter Me' is an Emmy Award-winning PBS series that is produced by Steven Latham Productions and powered by Petco Love. About OS Therapies OS Therapies is excited to be partnering with Shelter Me. OS Therapies is a biotechnology company developing treatments for Osteosarcoma (OS) and other solid tumors in humans and canines. OST-HER2 is an immunotherapy leveraging the immune-stimulatory effects of bacteria to initiate a strong immune response targeting the HER2 protein. In Osteosarcoma, OST-HER2 has completed Phase I & Phase III trials in canines and recently a Phase IIb clinical trial in humans, these were highlighted in 'Shelter Me: The Cancer Pioneers". In humans, OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. In canines, OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit
Associated Press
25-03-2025
- Business
- Associated Press
OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
OS Therapies (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2. The movie will premiere on April 3, 2025 at AMC Century City in Los Angeles and will be available to stream through the PBS app and on starting in May. 'Our team is dedicated to advancing a treatment for osteosarcoma and are proud to see our immunotherapy in Shelter Me: The Cancer Pioneers,' stated OS Therapies' CEO Paul Romness. 'Comparative oncology is an important area of research for us because of the striking genetic homology of over 96% between human and canine osteosarcoma.' OST-HER2 is an investigational drug and is not currently approved to treat osteosarcoma or any other disease. Shelter Me: The Cancer Pioneers also features leading scientists at the National Cancer Institute / National Institutes of Health, the University of Pennsylvania, the University of Illinois, the University of Wisconsin, and Colorado State University. It is part of an Emmy Award-winning PBS series, Shelter Me, that celebrates the life-changing relationships between people and animals. A trailer of the movie can be viewed here. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as 'anticipate,' 'expect,' 'intend,' 'may,' 'will,' 'should' or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's registration statement on Form S-1 filed with the Securities and Exchange Commission (the 'SEC') on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Jack Doll 571.243.9455 [email protected]:// SOURCE: OS Therapies Copyright Business Wire 2025. PUB: 03/25/2025 07:40 AM/DISC: 03/25/2025 07:39 AM
